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Abstract
Background: A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these
therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in
immunogenic epitopes presented by the cancer cells under inflammatory or non-inflammatory conditions.
The antigen processing machinery of the cell, the proteasome, cleaves proteins into peptide epitopes for
presentation on MHC complexes. Immunoproteasomes in inflammatory melanomas, and in antigen presenting
cells of the immune system, are enzymatically different to standard proteasomes expressed by tumors with no
inflammation. This corresponds to alterations in protein cleavage between proteasome subtypes, and a disparate
repertoire of MHC-presented epitopes.
Methods: We assessed steady state and IFNγ-induced immunoproteasome expression in melanoma cells. Using
epitope specific T-lymphocyte clones, we studied processing and presentation of three NY-ESO-1 HLA-Cw3
restricted epitopes by melanoma cell lines. Our experimental model allowed comparison of the processing of three
distinct epitopes from a single antigen presented on the same HLA complex. We further investigated processing of
these epitopes by direct inhibition, or siRNA mediated knockdown, of the immunoproteasome catalytic subunit
LMP7.
Results: Our data demonstrated a profound difference in the way in which immunogenic T-lymphocyte epitopes
are presented by melanoma cells under IFNγ inflammatory versus non-inflammatory conditions. These alterations
led to significant changes in the ability of T-lymphocytes to recognize and target melanoma cells.
Conclusions: Our results illustrate a little-studied mechanism of immune escape by tumor cells which, with
appropriate understanding and treatment, may be reversible. These data have implications for the design of cancer
vaccines and adoptive T cell therapies.
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Background
Although immune recognition of cancer occurs fre-
quently, spontaneous immune responses leading to clin-
ical benefit in cancer patients are rare [1, 2]. This failure
of effective immunity may result from tumor-mediated
immune suppression and evasion. Immunotherapies that
counter these mechanisms, such as immune checkpoint
inhibition [3, 4] and adoptive transfer of T-lymphocytes
[5], have been successfully developed for melanoma and
other cancers. These approaches have established that
functional T-lymphocytes capable of recognizing specific
HLA-peptide complexes on cancer cells can mediate
powerful anti-tumor effects. Nevertheless, many patients
fail to respond to these therapies, and vaccines designed
to generate or enhance specific immunity against tumor
antigens have largely been unsuccessful [2]. Further, it is
becoming clear that the nature of the tumor microenvir-
onment has a large role to play in success of treatment.
For example, in melanoma, the presence of tumor infil-
trating lymphocytes (TILs); the frequency of neo-
epitopes arising from tumor specific mutations; and the
presence of an interferon–gamma related immune signa-
ture have all been correlated with positive outcomes for
immune checkpoint inhibition [6–8]. Consequently the
concept has emerged that a T-lymphocyte/IFNγ in-
flamed tumor microenvironment carries positive predict-
ive value for responses to immunotherapy.
With regards to the latter, pro-inflammatory cytokines
such as IFNγ affect many facets of immunity within the
tumor microenvironment, such as the induction of the
immune checkpoint molecule PD-L1, cell surface MHC
expression, and the configuration of the protein-degrading
proteasome complex. These mechanisms can profoundly
influence the recognition of tumor antigens by T lympho-
cytes. Here, we establish the impact of inflammatory con-
ditions on melanoma cells and the consequences of
subsequent alterations in the proteasome complex, on T
lymphocyte mediated cancer cell recognition.
The degradation of cellular proteins by the proteasome
is a critical step in the generation of MHC-associated
peptides for presentation to cytotoxic CD8+ T lympho-
cytes [9]. The proteasome is a barrel shaped complex
consisting of four stacked rings, each with seven sub-
units [10]. The outer two rings are composed of struc-
tural α-subunits, and the inner two consist of catalytic β
subunits. The constitutive ‘standard’ proteasome and the
IFN-γ-induced immunoproteasome (IP) differ in their
use of three catalytic β subunits. In the immunoprotea-
some complex, subunits LMP-2, LMP-7 and MECL1 re-
place the β1, β5 and β2 subunits respectively, resulting
in changes in enzymatic activity and production of an al-
tered MHC class I epitope repertoire (reviewed in [11]).
Dendritic cells (DC) constitutively express IP at high
levels, [12, 13] whereas tumor cells [14], and specifically
melanoma cells [15], are generally described to infre-
quently express IPs or to express the LMP-2 and −7 sub-
units at low levels. The potential therefore arises for a
different repertoire of epitopes to be produced by DC
and tumor cells, and a number of epitopes from
melanoma-associated antigens have been described as
being differentially processed between the two prote-
asome subtypes [16]. This phenomenon may be mir-
rored between tumors with inflammatory versus non-
inflammatory microenvironments where epitopes pre-
sented by DC for priming of T-lymphocytes will more
closely reflect the epitope repertoire of inflammatory
tumors.
The cancer testis antigen (CT Ag) NY-ESO-1, and its
numerous T-lymphocyte epitopes have been defined and
studied in detail [17, 18]. Here, we utilize NY-ESO-1 as
a prototypic tumor antigen to investigate how differ-
ences in proteasome subtypes can contribute to tumor
escape from T lymphocyte recognition. By comparing
the processing of three different HLA-Cw3 restricted
NY-ESO-1 epitopes; 92–100, 96–104 and 124–133 [19,
20] we show that inflammation mediated changes in this
process can lead to a failure to present appropriate tar-
get antigens to cytotoxic T lymphocytes. We demon-
strate that optimal processing of each of the NY-ESO-1
epitopes is dependent on different proteasome subtypes,
with significant corresponding impact on T-lymphocyte
recognition and killing of melanoma cells. Our results
comprehensively illustrate the potential for an extraor-
dinary level of disparity in antigen presentation depend-
ing on the proteasome subtype present in the cell.
Importantly, this study illustrates a mechanism whereby
intratumoral inflammation (or lack of it) has the poten-
tial to profoundly affect T-lymphocyte killing.
Results
Immunoproteasome subunits are differentially expressed
in melanoma cell lines
We assessed the mRNA expression levels of standard pro-
teasome subunits (PSMB5 [Swiss-Prot:P28074], PSMB6
[Swiss-Prot:P28074], PSMB7 [Swiss-Prot:Q99436]) and
immunoproteasome (IP) subunits (PSMB8 [Swiss-
Prot:P28062], PSMB9 [Swiss-Prot:P28065], PSMB10
[Swiss-Prot:P40306]) in our database of 55 melanoma cell
lines by gene expression array analysis [21, 22] (Fig. 1). In
line with previous reports, we found that standard prote-
asome subunits were expressed by all of our cell lines [15].
Interestingly however, the IP subunit PSMB10 was also
expressed by the majority of our cell lines under steady
state conditions. Expression of the IP subunit PSMB8
was variable, detected in some cell lines and not in
others, while the third IP-specific subunit, PSMB9,
was detected in only a few cell lines. The PSMB11
subunit is a component of the specialized thymus
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restricted thymoproteasome, and its expression was
not detected in any of our cell lines [23].
We next evaluated expression of the protein products
of constitutive proteasome subunit genes PSMB5 and
PSMB6 (β5 and β1 respectively), and IP subunit genes
PSMB8 and PSMB9, (LMP7, LMP2) by Western blot in
4 selected cell lines. Since expression of the IP is upregu-
lated by IFNγ [24, 25] we assessed proteasome subunit
expression both under steady state conditions, and fol-
lowing 72 h incubation with IFNγ (Fig. 2). Even in the
absence of IFNγ, some LMP2 and LMP7 expression was
observed, which in all cell lines tested was upregulated
following incubation with IFNγ, (quantified by densitom-
etry analysis, Fig. 2, bottom panel). A concomitant de-
crease in expression of the constitutive proteasome
subunits β1 and β5 was observed following IFNγ treat-
ment of the same cell lines (Fig. 2).
Change in proteasome subunit expression alters
processing and presentation of NY-ESO-1 epitopes
For the well-studied cancer-testis antigen, NY-ESO-1,
three HLA-Cw3 restricted epitopes have been defined;
namely, NY-ESO-192–100, NY-ESO-196–104 and NY-ESO-
1124–133 [19, 20]. Using PBMC from melanoma patients
we isolated and expanded T-lymphocyte clones which
recognized each of these epitopes. The specificity of each
T-lymphocyte clone was confirmed by titration against
peptide coated PBMC (not shown).
To determine the effect of constitutive- versus
immuno- proteasome processing on antigen presenta-
tion by melanoma cells, we selected HLA-Cw3+, NY-
ESO-1 expressing cell lines and induced IP expression in
each by incubation with IFNγ. We compared subsequent
processing and surface presentation of each HLA-Cw3
restricted T-lymphocyte epitope in two ways. Firstly, we
determined the ability of specific T-lymphocyte clones to
lyse melanoma cells either under steady state conditions
(Fig. 3a, c, e), or following induction of an IP (Fig. 3b, d,
f ). Secondly, we assessed activation of each T-
lymphocyte clone in response to melanoma cell lines
treated +/− IFNγ, by measuring TNFα secretion (Fig. 3g,
h, i). Induction of an IP resulted in significant changes
in T-lymphocyte mediated tumor killing or recognition
for each of the three epitopes tested, which
Fig. 1 Proteasome subunit expression in melanoma cells lines. Hierarchical clustering of a panel of 55 early passage melanoma cell lines based
on expression of standard proteasome subunits PSMB5, PSMB6, PSMB7, corresponding immunoproteasome (IP) subunits PSMB8, PSMB9, PSMB10,
and thymus restricted subunit PSMB11
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demonstrated that epitope presentation on the cell sur-
face had altered.
Our results showed that each of the three NY-ESO-1
epitopes tested was processed in a different manner. In
most cases T-lymphocytes recognizing the NY-ESO-192–
100 and NY-ESO-196–104 epitopes could lyse melanoma
cells under steady state conditions (Fig. 3a, c). Of the
two epitopes, T-lymphocytes recognizing the NY-ESO-
196–104 epitope were generally more effective at baseline
killing of these cell lines. However, following induction
of an IP in the same cell lines T-lymphocyte mediated
tumor lysis was significantly enhanced by NY-ESO-192–
100 or NY-ESO-196–104 specific T-lymphocytes in 3/4 and
2/4 cell lines tested respectively (Fig. 3b, d). An increase
in killing of up to ~43 % mediated by NY-ESO-192–100
specific T-lymphocytes was observed at a 10:1 E:T ratio
(range: 4.3–42.82 %; mean: 23.88 %), and up to ~57 %
increased melanoma lysis (range: 0–57.37 %; mean:
19.71 %) mediated by NY-ESO-196–104 specific T-
lymphocytes at a 10:1 E:T ratio (Fig. 3b, d). Complemen-
tary results were observed for activation of T-
lymphocytes recognizing these epitopes on melanoma
cell lines treated under the same conditions. In both
cases the percentage of activated T-lymphocytes (secret-
ing TNFα) was increased following incubation of melan-
oma cells with IFNγ (Fig. 3g, h).
In contrast, processing of the NY-ESO-1124–133 epitope
decreased following induction of the IP in the same cell
lines. Specific T-lymphocyte mediated lysis and recogni-
tion of this epitope were both reduced significantly in 3/
4 cell lines following IFNγ treatment, compared to under
steady state conditions when the constitutive prote-
asome was expressed (Fig. 3e, f, i). Melanoma cell lysis
by T-lymphocytes recognizing NY-ESO-1124–133 was de-
creased by up to ~21 % at 10:1 E:T ratio (range: 2.46–
21.63 %, mean:12.41 %) when the IP was present.
Since incubation with IFNγ is known to upregulate
HLA Class I on the cell surface [26], we sought to con-
firm that the enhanced T-lymphocyte killing/recognition
observed for NY-ESO-192–100 and NY-ESO-196–104 epi-
topes was not simply due to increased surface HLA. We
coated melanoma cells with NY-ESO-192–100 or NY-
ESO-196–104 peptides, thereby saturating the HLA mole-
cules, and assessed specific T-lymphocyte cytoxicity
(Additional file 1: Figure S1). In comparison with melan-
oma cells which presented NY-ESO-1 epitopes directly
(i.e. were not peptide loaded), cells loaded with either
peptide underwent significantly greater lysis mediated by
their cognate T-lymphocyte. These results confirm that
HLA levels under steady state conditions were not a lim-
iting factor for surface presentation of antigen in these
experiments, and ruled out the possibility that an in-
crease in HLA alone would account for an increase in
T-lymphocyte mediated cell lysis. Indeed, this was in any
case implied by the results showing decreased recogni-
tion of the NY-ESO-1124–133 epitope in presence of
IFNγ.
As a means of directly assessing HLA-presentation of
each epitope, we isolated HLA class I complexes by im-














































LM-MEL-28 LM-MEL-42 LM-MEL-44 LM-MEL-53
Fig. 2 Effect of IFNγ on proteasome subunit expression in melanoma cells lines. Selected melanoma cell lines were incubated +/− IFNγ (100 ng/
ml, 72 h) and changes in expression of proteasome subunits was determined by Western blot. (Top panels) Expression of the IP subunits LMP2,
LMP7 and the standard proteasome subunits β1 and β5 were assessed under steady state and IFNγ treated conditions. (Bottom panels) Expression
of each subunit was quantified by densitometry analysis using Image Studio software. All blots shown here have been cropped from the original,
and some changes to the contrast/brightness have been made for purposes of clarity using Image Studio software
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antibodies DT9 (HLA-C specific) and W6/32 (pan anti-
HLA-A,-B,-C) covalently linked to protein A sepharose.
The bound peptides were eluted under mild acidic con-
ditions, fractionated by RP-HPLC and analyzed by mul-
tiple reaction monitoring (MRM), a targeted mass
spectrometry approach which is used to quantify indi-
vidual peptides in complex mixtures. Despite the unpar-
alleled sensitivity of this technique, we failed to detect
presentation of any of these three peptides under either
steady state conditions, or following IFNγ treatment
(data not shown). This result was disappointing,
however not entirely unexpected. Previous studies have
highlighted sensitivity of peptide purification by antibody
pulldown as a limiting factor of this approach, and it is
clear that specific T-lymphocytes have greater sensitivity
for their cognate epitope [27].
Knockdown of PSMB8 by siRNA reverts
immunoproteasome mediated processing of NY-ESO-1
HLA-Cw3 restricted epitopes
In the process of formation of an IP, the LMP7 subunit
is required for processing of other IP specific subunits
Fig. 3 Processing of NY-ESO-1 HLA-Cw3 restricted epitopes by melanoma cells expressing standard or immunoproteasomes. Selected melanoma
cell lines were incubated in presence or absence of IFNγ for 72 h to induce expression of the immunoproteasome. Cells were plated in wells of a
96 well flat-bottom plate at 104/well. T-lymphocyte clones specific for NY-ESO-1 HLA-Cw3 restricted epitopes 92–100, 96–104, or 124–133 were
added to each cell line at the effector:target (E:T) ratios shown (a–f) or at 5 × 104/well (g, h). Cytotoxicity assays, (a–f): Samples were incubated for
4 (a–d) or 24 h (e, f) at 37 °C. T-lymphocyte mediated cytotoxicity was determined by calcein release (a–d), or by MTS assay (e, f) and normalized
to maximum /spontaneous lysis control wells. Asterisks in the IFNγ treated panels (b, d, f) indicate statistical significance of the change in killing
between the equivalent cell line under steady state conditions (a,c,e). Intracellular cytokine stain, (g, h, i): Samples were incubated for 4 h in
presence of brefeldin A. T-lymphocytes were incubated with fluorescent antibodies for CD3 and CD8 and stained intracellularly with anti-TNFα
antibody, followed by FACS analysis. Error bars represent SEM (n = 3). Ns = not significant >0.05; * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001
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and assembly of intact IP [28]. LMP7 is also a compo-
nent of two described intermediate proteasome subtypes
[29]. Because these roles of LMP7, we knocked down
the expression of the corresponding gene, PSMB8, by
siRNA (Fig. 4a) and confirmed knockdown at the pro-
tein level (Fig. 4b) in melanoma cell lines. These melan-
oma cells were incubated +/− IFNγ, and the ability of
NY-ESO-1 specific HLA-Cw3 restricted T-lymphocytes
to recognize or kill melanoma cells lines was assessed
(Fig. 4c-h). As previously observed treatment of cell lines
with IFNγ resulted in enhanced presentation of the NY-
ESO-192–100 and NY-ESO-196–104 epitopes, while presen-
tation of NY-ESO-1124–133 decreased (Fig. 4c–h).
The knockdown of LMP7 resulted in complete abroga-
tion of the IFNγ induced enhancement of T-lymphocyte
cytotoxicity and recognition of the NY-ESO-192–100 and
NY-ESO-196–104 epitopes in most cases (Fig. 4c, d, f, g).
For the NY-ESO-192–100 epitope, T-lymphocyte activa-
tion following exposure to melanoma cells treated with
IFNγ in conjunction with PSMB8 knock-down, was sub-
stantially decreased in comparison to IFNγ together with
control siRNA, and indeed was reduced to below that of
untreated control cells (Fig. 4c), most likely reflective of
knockdown of low level PSMB8 expression in these cell
lines under steady state conditions (Fig. 1). NY-ESO-192–
100 specific T-lymphocyte mediated killing was also
reverted by concomitant IFNγ treatment and PSMB8
knockdown (Fig. 4f ). In the LM-MEL-44 cell line, this
effect was profound, and these T-lymphocytes were ef-
fectively unable to lyse this cell line when the LMP7
component of the proteasome was not present. The ef-




































































































































































Fig. 4 Processing of NY-ESO-1 HLA-Cw3 restricted epitopes following PSMB8 siRNA knockdown in melanoma cell lines. PSMB8 expression was
knocked down by siRNA in melanoma cell lines and knockdown was confirmed at mRNA (a) and protein (b) levels following 72 h incubation.
Following 72 h of PSMB8 knockdown alongside incubation +/− IFNγ, T-lymphocyte recognition (c–e) or cytotoxicity (f–h) was assessed and
compared to cells treated with scrambled control siRNA. (c–e): T-lymphocytes were incubated with melanoma cells for 4 h in presence of
Brefeldin A and cytokine secretion was determined by intracellular staining, followed by FACS analysis. f–h: T-lymphocytes were incubated with
melanoma cells at a 1:1 effector:target ratio for 24 h at 37 °C, then washed off. T-lymphocyte mediated cytotoxicity was determined by MTS assay
and normalized to control wells with no T-lymphocytes. Error bars represent SEM (n = 3). Ns = not significant >0.05; * < 0.05; ** < 0.01; *** < 0.001
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T-lymphocyte mediated killing was less profound, how-
ever in one cell line specific lysis was significantly de-
creased following IFNγ/PSMB8 siRNA treatment
compared to cell lines treated with IFNγ and control
siRNA (Fig. 4g). Similarly T-lymphocyte recognition of
this epitope, enhanced by induction of the IP, was sig-
nificantly abrogated following PSMB8 knockdown
(Fig. 4d). Processing of the NY-ESO-1124–133 epitope
was, in contrast, restored significantly following PSMB8
knockdown, although in most cases did not reach levels
equivalent to T-lymphocyte cytotoxicity/recognition
prior to IFNγ treatment of these cells (Fig. 4e, h).
Inhibition of LMP7 reverts immunoproteasome mediated
processing of NY-ESO-1 HLA-Cw3 restricted epitopes
The small molecule inhibitor PR-924 (gift from Onyx
Pharmaceuticals) selectively inhibits the immunoprotea-
some subunit LMP7 by specific binding to its active site
[30]. The LMP7 enzymatic active site is only exposed in
intact immunoproteasomes and use of this inhibitor
does not affect the overall LMP7 protein level in the cell
(Additional file 2: Figure S2a). We found that our melan-
oma cells lines had increased sensitivity to PR-924 fol-
lowing co-incubation with IFNγ (Additional file 2:
Figure S2b). Nevertheless, the inhibitor was still effective
at blocking LMP7 specific enzymatic activity at
concentrations where melanoma cells remained viable,
which varied depending on the cell line used (Additional
file 2: Figure S2c).
Melanoma cell lines were incubated with PR-924 in
presence/absence of IFNγ for 72 h and the ability of NY-
ESO-1 specific HLA-Cw3 restricted T-lymphocytes to
recognize or kill melanoma cells lines was assessed
(Fig. 5). As previously observed enhanced presentation
of the NY-ESO-192–100 and NY-ESO-196–104 epitopes,
and decreased processing of the NY-ESO-1124–133 epi-
tope occurred following IFNγ treatment.
NY-ESO-192–100 specific T-lymphocyte recognition/
cytotoxicity was generally not significantly affected fol-
lowing incubation with PR-924 alone (Fig. 5a, d). When
melanoma cells were incubated in presence of both PR-
924 and IFNγ, T-lymphocyte responses were significantly
reduced compared to with melanoma cells treated with
IFNγ alone, and reverted to activation/cytoxicity levels
comparable with, or even less than, those observed for
cells treated with PR-924 alone in most cases.
For the NY-ESO-196–104 epitope, incubation of melan-
oma cell lines with PR-924 alone had generally little ef-
fect on T-lymphocyte recognition or cytotoxicity,
however co-incubation with PR-924 and IFNγ resulted
in decreased T-lymphocyte responses compared to IFNγ




























































































































































Fig. 5 Processing of NY-ESO-1 HLA-Cw3 restricted epitopes following LMP7 inhibition in melanoma cell lines. The enzymatic activity of the
immunoproteasome subunit LMP7 was inhibited by incubation of melanoma cell lines with the small molecule inhibitor PR-924, in presence or
absence of IFNγ. Following 72 h, T-lymphocytes were added and activation (a–c) or cytoxicity (d–f) was assessed for each of the treatment
conditions. a–c T-lymphocytes were incubated with melanoma cells for 4 h in presence of Brefeldin A and cytokine secretion was determined by
intracellular staining, followed by FACS analysis. d–f T-lymphocytes were incubated with melanoma cells at a 1:1 effector:target ratio for 24 h at
37 °C, then washed off. T-lymphocyte mediated cytotoxicity was determined by MTS assay and normalized to control wells with no T-
lymphocytes. Error bars represent SEM (n = 3). ns = not significant >0.05; * < 0.05; *** < 0.001
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with standard proteasome mediated processing of this
epitope (Fig. 5b, e).
In some cases processing of the NY-ESO-1124–133 epi-
tope was slightly enhanced following incubation with
PR-924 alone, most likely corresponding to inhibition of
minimal immunoproteasome subunits present under
steady state conditions (Fig. 5c, d). Treatment of melan-
oma cells with both PR-924 and IFNγ also slightly en-
hanced T-lymphocyte responses to the NY-ESO-1124–133,
however not significantly or to the levels observed under
steady state conditions.
Immunoproteasome expression is correlated with T
lymphocyte infiltration in human biopsies
Biopsies from melanoma patients were evaluated by an
independent pathologist for the presence of tumor infil-
trating lymphocytes (TILs). TILs were scored as being
either ‘absent’ or ‘brisk’ [31]. Tumors with brisk TIL in-
filtrates were deemed to demonstrate inflamed condi-
tions with a likelihood of corresponding IFNγ expression
from inflammatory cells [7, 8]. In order to evaluate the
IP expression biopsies were selected from individual pa-
tients who had more than one metastasis and where
paired metastases from these individuals were disparate
for TIL. Formalin fixed paraffin embedded (FFPE) tumor
sections were stained for the expression of the IP (either
LMP2 or LMP7) and presence of CD3+ TILs. In 3/3 pa-
tients tested, we found that when TILs were absent, IP
expression was not detectable. In contrast, both LMP2
and LMP7 were consistently expressed in the presence
of TILs, (Fig. 6, representative donor). We found that in
sections from a single biopsy, regions which lacked TILs
also lacked IP subunit expression, i.e. IP expression was
not uniform throughout the ‘inflamed’ tumor. Instead,
there was a clear correlation in expression of IP subunits
and CD3+ cells.
Discussion
The immune recognition of cancer antigens following
vaccination may fail because APC and cancers can gen-
erate antigens using different processing machinery. Pre-
vious reports have shown that differences in proteasome
form can alter processing of individual peptides [32].
Here we have extended those studies by comparing three
epitopes from a single tumor antigen (NY-ESO-1) which
are presented by the same HLA complex (HLA-Cw3).
Our results clearly demonstrate that a mismatch occurs
between the specificities of epitopes that were generated
between tumor cells under inflammatory/non-inflamma-
tory conditions. This is the first demonstration that pro-
cessing of a number of epitopes derived from the same
tumor antigen can vary depending on the proteasome
subtype and subsequent processing of the antigen. Of
particular interest is the observation that processing of
one epitope (NY-ESO-1124–133) was decreased via the IP.
There is precedence for decreased processing of individ-
ual immunogenic epitopes via the IP (e.g. Melan A26–35
[13]), however this has not been previously shown to
LMP7
LMP2
Absent TILs Brisk TILs
CD3; LMP2/7; DAPICD3; LMP2/7; DAPI
Absent TILsBrisk TILs
Fig. 6 Immunoproteasome expression in melanoma biopsies. Formalin fixed paraffin embedded human melanoma biopsies from a single patient
were scored by a pathologist as having ‘absent’ or ‘brisk’ tumor infiltrating lymphocytes (TILs) present, as labeled. 4 μM sections were co-stained
for expression of CD3 to identify TILs, and either of the immunoproteasome subunits LMP2 or LMP7 as indicated. DAPI was used to visualize cell
nuclei. Images were acquired using a VECTRA automated quantitative pathology imaging system and analysis was performed using InForm
software. Images are shown as pseudo-brightfield IHC (left panels), or multifocal fluorescent images (right panels)
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occur asynchronously with other epitopes from the same
protein.
We demonstrated decreased processing in 4/4 NY-
ESO-1+, HLA-Cw3+ cell lines (Fig. 3e, f ), despite vari-
ability of these cell lines in their IP subunit expression
(Fig. 2). The IP knockdown and inhibition experiments
confirmed the dependence of NY-ESO-1124–133 on pro-
cessing via the standard proteasome. In these experi-
ments, NY-ESO-1124–133 processing in presence of IFNγ
could be partially or completely rescued by knockdown/
inhibition of PSMB8, since under these conditions only
standard proteasomes can be formed (siRNA) (Fig. 4e,
h), or are enzymatically active (Fig. 5c, f ).
Given these findings it seems likely that a mismatch
between vaccine-generated and tumor-displayed epi-
topes may occur with greater frequency than has been
previously appreciated, particularly if the tumor micro-
environment is uninflamed. This concept is supported
by the work of Saccheri et al. [33]. This group infected
melanoma cells with bacteria which facilitated the for-
mation of gap junctions between melanoma cells and
DC, and the subsequent direct transfer of melanoma
processed (via the standard proteasome) epitopes onto
DC. These DC were capable of inducing anti-tumor im-
munity which led to a decrease in tumor growth. DC in-
cubated with tumor lysate, necessitating cross
presentation of antigen via the immunoproteasome,
were less efficient at inducing anti-tumor immunity.
Further studies will be required to establish the extent
to which this contributes to the failure of cancer vac-
cines, nonetheless such observations become critical
when designing antigen-specific therapies, particularly
cancer vaccines and adoptive T-lymphocyte transfer
since the fine specificities of peptide antigens on target
cells will need to be taken into account.
We have performed a series of clinical trials where pa-
tients were vaccinated with full-length NY-ESO-1 re-
combinant protein (NCT00199901, NCT00518206) ([34]
and manuscript in preparation). They were undertaken
on the background of detailed studies of NY-ESO-1 epi-
topes and specific T cell responses [35–37]. These stud-
ies have demonstrated that the vaccine is effective at
generating diverse immune responses to many epitopes
restricted by a variety of HLA alleles [18, 38, 39]. Among
these, we have characterized responses to the NY-ESO-
192–100 and NY-ESO-196–104, epitopes which were gener-
ated in response to vaccination [34]. In contrast, NY-
ESO-1124–133 specific T-lymphocytes were found to
occur spontaneously but were not induced by vaccin-
ation. The clinical outcome of the most recent phase II
randomized clinical trial will be reported in due course,
however suffice to say, like many other reported vaccine
trials, it had little impact on patient survival. While there
are other mechanisms that can account for this
outcome, the findings described here highlight the possi-
bility that a dissociation between the peptides generated
by APC from those present on tumor may indeed be an
obstacle to effective cancer recognition. This possibility
is further supported by a recent clinical trial reported by
Dannull et al. showing that melanoma patients vacci-
nated with tumor antigen loaded DC, which had been
co-transfected with siRNA targeting the three IP sub-
units, developed T-lymphocyte responses with superior
lytic ability against autologous tumor compared to con-
trol siRNA transfected DC [40, 41].
The presence of IFNγ within the tumor microenviron-
ment has been shown to be associated with improved
clinical outcomes to both cancer vaccination and im-
mune checkpoint inhibition [7]. While IFNγ could influ-
ence immune recognition at a variety of levels, one now
obvious effect could be by correcting the disparity in
epitope repertoires between those displayed by APC and
tumor. Indeed, Donia et al. demonstrated that tumor
cells treated with IFNγ ex vivo were recognized better
by autologous TILs [42]. Our results clearly demonstrate
that upregulation of the IP occurs in the T lymphocyte
inflamed tumor microenvironment in vivo (Fig. 6). It is
tempting to speculate that the presence of TILs secret-
ing IFNγ leads directly to IP upregulation. Further study
is underway in our lab to further define the mechanism
of the in vivo upregulation of the IP, as well as to correl-
ate this with patient prognosis and/or response to
treatment. Immune checkpoint inhibitors are now rou-
tinely used in treatment of melanoma, and these anti-
bodies have the capacity to induce IFNγ at the tumor
site [43, 44]. Based on our results, other agents that in-
duce IFNγ at the tumor site may also facilitate enhanced
tumor recognition by T-lymphocytes that have been pre-
viously primed by DC to recognize IP generated epi-
topes. Our ongoing laboratory studies are addressing
this in pre-clinical models.
Since IFNγ upregulates PD-L1 expression by melan-
oma cell lines, [45] (Additional file 3: Figure S3 a,b) we
assessed whether concomitant treatment of melanoma
cells with IFNγ and PD-1 inhibitory antibody resulted in
further enhancement of T-lymphocyte lysis by T-
lymphocyte clones specific for the IP processed the NY-
ESO-192–100 epitope (Additional file 3: Figure S3c, d).
We demonstrated an additive effect for IP induction and
PD-1 inhibition when an appropriate T-lymphocyte epi-
tope was selected as a target.
Shared antigens such as NY-ESO-1 represent attractive
targets for immunotherapy, since they are widely
expressed in many cancer types and restricted to cancer.
Vaccines provide the potential to induce immune effec-
tors that can target cancer, an approach that is particu-
larly attractive when immune ignorance is an obstacle to
effective cancer immunotherapy. Based on our studies,
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however, vaccination alone may well be ineffective even
if effectors are generated, since they may fail to ad-
equately recognize their targets. This problem may be
readily overcome with a further refinement; the addition
of strategies that generate IFNγ in the tumor micro-
environment and induce IP expression. There are many
ways this could be achieved including antibody targeting
[46], oncolytic viruses [47], and the use of kinase inhibi-
tors. Such approaches clearly warrant clinical evaluation,
particularly in patient populations for whom existing im-
munotherapies fail to have impact.
Conclusions
We found that differences in proteasomes between in-
flamed and uninflamed tumors led to profound changes
in the generation of three distinct epitopes from a single
tumor antigen. The observed changes in epitope reper-
toire between inflamed and uninflamed tumors resulted
in significant differences in the ability of T lymphocytes
to target tumor cells. Our results demonstrate that
knowledge of the tumor microenvironment, and how to
manipulate it, may be critical for the success of cancer
vaccine or adoptive T cell therapies and that such ther-
apies may be more effective when combined with strat-
egies to induce inflammation at the tumor site.
Methods
Human ethics approval
Samples used in this study were derived from patients
who consented to participate in a clinical research
protocol approved by Austin Health Human Research
Ethics Committee (HREC H2006/02633).
Melanoma cell line culture
Establishment and characterization of the melanoma cell
lines used has been previously described [21, 22]. Cells
were cultured in RF10 consisting of RPMI 1640, 2 mM
Glutamax, 100 IU/ml Penicillin, 100 μg/ml Streptomycin
and 10 % heat-inactivated fetal calf serum (all Invitro-
gen). For induction of immunoproteasome catalytic sub-
units cells were incubated with 100 ng/ml IFNγ
(Peprotech) for 72 h prior to experiments. For inhibition
of PD-1, anti-PD-1 antibody (nivolumab, BMS) was
added at 10 μg/ml alongside the T-lymphocyte clones.
Gene expression array
The gene expression array dataset [22] and pre-processing
methods [48] have been previously described. Briefly,
RNA was purified from melanoma cell lines (Qiagen All-
Prep kits) and assayed using Illumina HT12 arrays follow-
ing the manufacturer’s protocols. Hierarchical clustering
was performed in Partek Genomic Suite using Euclidian
distance and average linkage.
Western blot
Melanoma cell line lysates were subjected to standard
Western blot using NuPAGE® SDS-PAGE pre-cast gels
(Invitrogen), and SeeBlue® Plus2 pre-stained protein
standards (Invitrogen). Primary antibodies and dilutions
were: rabbit anti-human LMP7 (1:1000), LMP2 (1:1000),
β5 (1:1000), β1 (1:500), GAPDH (1:2000), (all Abcam).
Dilutions were made in standard Tris Buffered Saline
with 5 % Bovine serum albumin and 0.05 % Tween20.
The secondary antibody was goat anti-rabbit IRDye 800
used at 1:20,000 dilutions. Antibody binding was visual-
ized using an Odyssey Imaging system and ImageStudio
Lite Ver 5.2 analysis software (LI-COR).
Generation and culture of NY-ESO-1 specific CD8+ T-
lymphocyte clones
CD8+ T-lymphocyte clones specific for the NY-ESO-1
HLA-Cw3-restricted peptides NY-ESO-192–100, NY-
ESO-196–104, and NY-ESO-1124–133 were generated from
patients who consented to participate in a clinical re-
search protocol approved by Austin Health Human Re-
search Ethics Committee (HREC H2006/02633). PBMC
were stimulated with 1 × 10−6 M peptide (Mimotopes),
and cultured for 10 days in the presence of 25 IU/ml IL-
2 (Peprotech). Specific cells were labeled with a fluores-
cent tetramer (comprising the relevant peptide and
HLA, (TCMetrix, Epalinges, Switzerland) and single-cell
sorted using a MoFlow cytometer. Clones were ex-
panded with pooled, autologous healthy donor PBMC as
feeder cells, 1 μg/ml phytohaemagglutinin-L (PHA-L
(Sigma)) and 600 IU/ml IL-2 (Cetus). After approxi-
mately 20 days, 1–10 × 103 clones were restimulated in
the presence of autologous PBMC as feeder cells, PHA-
L and IL-2, as described above. Clone specificity was
confirmed by tetramer staining.
T-lymphocyte clones/lines were cultured in RPMI
1640 media supplemented with 2 mM Glutamax,
100 IU/ml Penicillin, 100 μg/ml Streptomycin, 20 mM
HEPES, 1 % nonessential amino acids, 1 mM sodium
pyruvate, 55 μM β-mercaptoethanol, and 10 % human
serum (TCRPMI). IL-2 (100 IU/ml) was added and re-
placed every 3 days.
T-lymphocyte killing – Calcein release assay
Measurement of calcein release from labeled cells as a
means of determining T-lymphocyte mediated cytotoxicity
has been described previously [49]. Briefly, melanoma cells
were stained with 15 μM Calcein-AM reagent (Invitrogen)
for 30 min at 37 °C, then washed and plated in a 96-well
plate at 10,000 cells/well. T-lymphocytes were added to se-
lected wells as appropriate to give the effector to target
(E:T) ratios shown in the text. Samples were incubated for
4 h at 37 °C. Supernatants from each well were transferred
to a new 96-well plate, and fluorescence was measured
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using the Wallac plate reader (excitation 485 nm/emission
535 nm; 0.1 s). Percent cytotoxicity was calculated using
the formula: 100 × ([test value − spontaneous]/[max-
imum − spontaneous]), where ‘spontaneous’ is the meas-
urement from untreated control wells, and ‘maximum’ the
reading from cells lysed with 3 % Triton X-100 for 10 min
at 37 °C.
T-lymphocyte killing – MTS assay
Twenty thousand melanoma cells were plated in wells of
a flat bottom 96-well plate. T-lymphocytes were added
to selected wells as appropriate to give the effector to
target (E:T) ratios shown in the text/figure legends. Sam-
ples were incubated overnight (~16–24 h) at 37 °C. The
following day T-lymphocytes were resuspended by gentle
pipetting and then removed. The plate was washed once
with PBS. MTS reagent (CellTiter 96® AQueous One So-
lution Cell, Promega) was added and samples incubated
for 1–2 h at 37 °C. Absorbance at 490 nm was mea-
sured, and normalized to melanoma samples incubated
in absence of T-lymphocytes for each cell line to give
percentage of viable cells.
Intracellular cytokine staining (ICS) of antigen-activated T-
lymphocytes
Specific T-lymphocyte clones were incubated for 4 h
with melanoma cells in presence of 10 μg/ml brefeldin
A. Cells were labeled with live/dead fixable violet stain
(Invitrogen) according to the manufacturer’s instruc-
tions, then incubated with antibodies against CD3 (PE)
and CD8 (APC) (BD biosciences) for 15 min at 4 °C.
Samples were washed and fixed with fix/permeabilisa-
tion reagent (BD biosciences) for 20 min at 4 °C. Cells
were stained with anti-IFNγ-FITC and anti-TNFα-PECy7
(eBiosciences) in permeabilisation/wash solution (BD bio-
sciences) for 25 min at 4 °C. The gating strategy was: SSC/
LD−; CD3+/CD8+; CD8+/IFNγ+ or CD8+/TNFα+. Data
from at least 100,000 stained cells were acquired on a
FACSCanto and analyzed with FlowJo software. Data col-
lection and analysis was in accordance with the MIATA
guidelines [50].
Flow cytometry
For PD-L1 analysis, melanoma cells were incubated with
anti-CD274-PE (BD bioscience) at 1:50 dilution for
15 min at 4 °C.
Cells were washed twice in PBS then data from at
least 100,000 stained cells were acquired on a FACS-
Canto and analyzed with FlowJo software. Data col-
lection and analysis was in accordance with the
MIATA guidelines [50].
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR)
cDNA was generated using the High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems). Quantita-
tive polymerase chain reaction (qPCR) was performed
using the QuantiFast SYBR Green PCR Kit (Qiagen).
Primer sequences were as follows: NY-ESO-1, (forward)
5′-gagccgcctgcttgagtt-3′ and (reverse) 5′-agcactgcgtgatc-
cacatc-3′; PSMB8 (forward) 5′-catgggccatctcaatctg-3′,
and (reverse) 5′-agtagatttccgcgtcgaag-3′; β-actin (for-
ward) 5′-ctggaacggtgaaggtgaca-3′ and (reverse) 5′-
cggccacattgtgaactttg-3′
PR-924
PR-924 is an epoxyketone which selectively and irrevers-
ibly inhibits the LMP7 subunit [30, 51] (Onyx Pharma-
ceuticals, an Amgen subsidiary, kind gift). Inhibition of
LMP7 activity and viability varied between cell lines, and
was optimized for each cell line individually as discussed
in the text and shown in Additional file 2: Figure S2.
Chymotrypsin activity assay
Chymotryspin activity in melanoma cells was measured
using the Proteasome-Glo™ Chymotrypsin-like cell based
assay kit (Promega) according to the manufacturer’s
instructions.
siRNA
siRNA mediated interference was performed using ON-
TARGETplus SMARTpool siRNA reagents (Dharmacon)
for PSMB8, or scrambled control. Transfections were
performed using the RNAiMAX reagent (Life Technolo-
gies) and according to the manufacturer’s instructions.
Melanoma cell lines were plated at ~60 % confluency
and siRNA reagents added at a final concentration of 10
nM. Cells were incubated for 72 h at 37 °C prior to use
in experiments.
Purification of HLA bound peptides
HLA bound peptides were isolated by immunoaffinity
chromatography and reverse-phase high-performance li-
quid chromatography (RP-HPLC) essentially as de-
scribed before [52, 53]. In brief, 109 cells were lysed in
0.5 % IGEPAL, 50 mM Tris–HCl pH 8.0, 150 mM NaCl
and protease inhibitors (CompleteProtease Inhibitor
Cocktail Tablet; Roche Molecular Biochemicals) for
45 min at 4 °C. The lysate was cleared by ultracentrifu-
gation at 40,000 g and the HLA class I complexes were
immunoaffinity purified using a combination of DT9
(HLA-C specific) and W6/32 monoclonal antibody (pan
anti-HLA-A, B, C) covalently linked to protein A seph-
arose (GE Healthcare). The bound peptides were eluted
by acidification with 10 % acetic acid and separated from
the class I heavy chains and ß2m molecules on a 50 mm
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monolithic C18 RP-HPLC column (Chromolith Speed
Rod; Merck) using an EttanLC HPLC system (GE
Healthcare).
Multiple Reaction Monitoring (MRM)
Skyline v2.1.0.4936 [54] was used to design MRM transi-
tions for the NY-ESO-1 HLA-Cw3-restricted peptides
NY-ESO-192–100, NY-ESO-196–104, and NY-ESO-1124–133.
For each peptide, the four most abundant b- and y-
fragment ions of the predominant precursor ion were se-
lected based on the peptide’s fragmentation pattern on a
5600+ TripleTOF mass spectrometer (AB SCIEX). For
MRM detection, a QTRAP 5500 mass spectrometer (AB
SCIEX) coupled to a NanoUltra cHiPLC system (Eksi-
gent) was used as described previously [55].
Immunohistochemistry
4 μM sections were cut from formalin fixed paraffin em-
bedded (FFPE) biopsy blocks from selected melanoma
patients, and mounted on glass slides. Samples were
dewaxed using xylene, then dehydrated by sequential in-
cubation in 100 %, 70 % ethanol, followed by hydrogen
peroxide.
Antigen was retrieved by boiling for 15 min in citrate
buffer, pH 6.0 (Thermo Scientific). Following cooling/
washing with TBST (Thermofisher), slides were blocked
by 30 min incubation with Background Sniper reagent
(Biocare medical). Slides were then incubated for 1 h
with the first primary antibody, either rabbit-anti human
LMP2 (Abcam, ab3328) or rabbit-anti-human LMP7
(Abcam, ab3329). Both were used at 0.1 μg/ml diluted in
antibody diluent (DAKO). Anti-rabbit-HRP-polymer
(DAKO) was added for 30 min, followed by a 1/50 dilu-
tion of OPAL-570 TSA in amplification diluent (both
from the OPAL 4-color fluorescent IHC kit, Perkin
Elmer) for 10 min.
Samples were boiled for 3 min in citrate buffer, pH 6.0
and the above steps were repeated with the second pri-
mary antibody, rabbit anti-human CD3 (Abcam, SP7),
used at 1/1500 dilution. The only difference in this
round of staining was that OPAL-520 TSA (1/50) was
used as the fluorophore.
Samples were boiled in citrate buffer, pH 6.0, then
stained with DAPI (Life Technologies) diluted 1/2000 in
water, for 5 min at room temperature. Coverslips were
mounted to slides using Vectashield HardSet Mounting
medium (Abacus).
Additional files
Additional file 1: Figure S1. T-lymphocyte mediated lysis of melanoma
cell lines is not limited by HLA. Melanoma cell lines were either
untreated, or pulsed with 92–100 or 96–104 peptide (1 μM/ml for 2 h at
room temperature). T-lymphocytes recognising the relevant epitope were
incubated with melanoma cells (peptide loaded (right panels) or not (left
panels)) and following overnight incubation, percentage cytotoxicity was
determined by calcein assay. Results demonstrate that T-lymphocyte
mediated cytotoxity of melanoma cells is not limited by HLA, but rather
by levels of antigen present on the cell surface. (PDF 11 kb)
Additional file 2: Figure S2. Effect of PR-924 on melanoma cell viability
and enzymatic activity. (A) Since PR-924 inhibits only intact, enzymatically
active immunoproteasomes, expression of LMP7 (target of PR-924) was
detected by Western blot before and after induction with IFNγ, and in
the presence of PR-924 for 72 h. (B) Melanoma cells were incubated for
72 h with a dose range of PR-924 as shown, in presence or absence of
IFNγ. Viability was determined by MTS assay. IC50 was variable between
cell lines, and was reduced following IFNγ incubation in all cases. Error
bars represent SEM. (C) The LMP7 subunit has chymotrypsin-like
enzymatic activity. PR-924 activity was confirmed in melanoma cell lines
treated with IFNγ, using a chymotrypsin-like assay (Promega) for
enzymatic activity of LMP7 at different doses as indicated. (PDF 65 kb)
Additional file 3: Figure S3. Effect of PD-1 inhibition on T-lymphocyte
lysis of IFNγ treated melanoma cell lines. Melanoma cell lines were
incubated in presence or absence of IFNγ for 72 h at 37 °C. (A, B) Cells
were stained with anti-CD-274 (PD-L1)-APC antibody and the percentage
PD-L1 positive melanoma cells was determined by FACS analysis. (C, D).
Melanoma cells, pre-treated +/− IFNγ for 72 h were incubated with T-
lymphocyte clones specific for NY-ESO-192–100, at 1:1 effector:target ratio,
for 24 h at 37 °C, in presence or absence of anti-PD-1 inhibitory antibody
(10 μg/ml). T-lymphocytes were washed off following the incubation
period and T-lymphocyte mediated cytotoxicity was determined by MTS
assay, normalized to control wells with no T-lymphocytes. Error bars
represent SEM (n = 3). ns = not significant >0.05; * < 0.05; ** < 0.01.
(PDF 12 kb)
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